125629 [BETTER]

Shaji K. Kumar, Robert F. Cornell, Ola Landgren, Sikander Ailawadhi, Jack P Higgins, Erin K Willert, Roger Waltzman, Jianchang Lin, Yuhong Zhang, Anya R Lublinsky, Ajeeta B Dash, Michael Hanley, Divya Manoharan, Morgan Leichter, Sean Ottinger, Richard J Labotka, John Newcomb, Alexander Vorog; A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara). Blood 2019; 134 (Supplement_1): 1867. doi: -2019-125629

125629

041b061a72